Breaking News Instant updates and real-time market news.

PTE

PolarityTE

$5.56

-0.07 (-1.24%)

17:11
06/12/19
06/12
17:11
06/12/19
17:11

PolarityTE director Gorlin sells 53.7K shares of common stock

In a regulatory filing, PolarityTE disclosed that its director Steve Gorlin solid 53.7K shares of common stock on June 10th. The total transaction size was $319K.

PTE PolarityTE
$5.56

-0.07 (-1.24%)

04/08/19
OPCO
04/08/19
NO CHANGE
Target $30
OPCO
Outperform
Data from DLS meeting give 'major boost' to SkinTE outlook, says Oppenheimer
Oppenheimer analyst Kevin DeGeeter said data presented on April 5 at the Diabetic Limb Salvage meeting were "dramatically better than the 0-25% complete healing rate we would have expected" in diabetic foot ulcer patients, which he views as giving a "major boost" to the outlook for SkinTE in chronic wounds. DeGeeter maintains an Outperform rating on PolarityTE with a $30 price target.
04/08/19
CANT
04/08/19
NO CHANGE
CANT
Cantor reiterates Overweight rating on PolarityTE after recent presentations
Cantor Fitzgerald analyst Elemer Piros reiterated an Overweight rating and $65 price target on PolarityTE following recent presentations at the Diabetic Limb Salvage, or DLS, Conference, including PolarityTE showing a 12-week study evaluating the application of SkinTE on 11 unique diabetic foot ulcers that failed previous therapies in which ten of the eleven, or 91%, of the wounds were closed by 12 weeks, and remained closed upon inspection two weeks thereafter. Piros believes these results "demonstrate the ability of SkinTE to work in difficult situations, with a high success rate."
04/30/19
CANT
04/30/19
NO CHANGE
Target $65
CANT
Overweight
PolarityTE's SkinTE may address certain genetic diseases, says Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros says PolarityTE's presentation yesterday highlighted differentiated case studies in which SkinTE was an effective treatment in restoring the regenerative properties of skin. In one case study, SkinTE was applied to correct a previous failed split-thickness skin graft, Piros tells investors in a research note. Although early, preclinical work shows a potential for SkinTE to address certain genetic diseases, contends the analyst. He believes upcoming data presentations at the Symposium on Advanced Wound Care Conference on May 7-11 is an "important upcoming catalyst." Piros thinks PolarityTE "can revolutionize the field of regenerative medicine." He reiterates an Overweight rating on the shares with a $65 price target.
05/10/19
PIPR
05/10/19
NO CHANGE
Target $26
PIPR
Overweight
Piper cuts 2019 sales estimate for PolarityTE's SkinTE by 75% to $5M
Piper Jaffray analyst Tyler Van Buren says that while adoption of PolarityTE's SkinTE is improving with the number of patients treated up 47% quarter-over-quarter in Q1, sales of $297,000 were below expectations due to an increase in the proportion of lower cost chronic wounds. Following the results, the analyst reset his near-term launch expectations and decreased his 2019 annual SkinTE sales estimate to $5M from $20M. However, Van Buren's long-term sales estimates are still largely intact at over $300M. As such, he keeps an Overweight rating on PolarityTE shares.

TODAY'S FREE FLY STORIES

COMM

CommScope

$15.62

-0.265 (-1.67%)

05:41
06/20/19
06/20
05:41
06/20/19
05:41
Upgrade
CommScope rating change  »

CommScope upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

TEL

TE Connectivity

$93.39

0.67 (0.72%)

05:40
06/20/19
06/20
05:40
06/20/19
05:40
Upgrade
TE Connectivity rating change  »

TE Connectivity upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JWN

Nordstrom

$33.18

1.04 (3.24%)

05:37
06/20/19
06/20
05:37
06/20/19
05:37
Upgrade
Nordstrom rating change  »

Nordstrom upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

PGSVY

PGS ASA

$0.00

(0.00%)

05:33
06/20/19
06/20
05:33
06/20/19
05:33
Downgrade
PGS ASA rating change  »

PGS ASA downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PDD

Pinduoduo

$20.96

0.08 (0.38%)

05:32
06/20/19
06/20
05:32
06/20/19
05:32
Initiation
Pinduoduo initiated  »

Pinduoduo initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CB

Chubb

$148.73

1.37 (0.93%)

05:30
06/20/19
06/20
05:30
06/20/19
05:30
Downgrade
Chubb rating change  »

Chubb downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

OPHLY

Ono Pharmaceutical

$0.00

(0.00%)

05:29
06/20/19
06/20
05:29
06/20/19
05:29
Downgrade
Ono Pharmaceutical rating change  »

Ono Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YARIY

Yara

$0.00

(0.00%)

05:27
06/20/19
06/20
05:27
06/20/19
05:27
Downgrade
Yara rating change  »

Yara downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZURVY

Zurich Insurance

$0.00

(0.00%)

05:26
06/20/19
06/20
05:26
06/20/19
05:26
Upgrade
Zurich Insurance rating change  »

Zurich Insurance upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRE

Bank of Ireland

$0.00

(0.00%)

05:24
06/20/19
06/20
05:24
06/20/19
05:24
Upgrade
Bank of Ireland rating change  »

Bank of Ireland upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DOC

Physicians Realty Trust

$18.27

0.095 (0.52%)

05:23
06/20/19
06/20
05:23
06/20/19
05:23
Initiation
Physicians Realty Trust initiated  »

Physicians Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HTA

Healthcare Trust

$29.18

0.16 (0.55%)

05:23
06/20/19
06/20
05:23
06/20/19
05:23
Initiation
Healthcare Trust initiated  »

Healthcare Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

HR

Healthcare Realty Trust

$33.14

0.26 (0.79%)

05:22
06/20/19
06/20
05:22
06/20/19
05:22
Initiation
Healthcare Realty Trust initiated  »

Healthcare Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

SCRYY

Scor

$0.00

(0.00%)

05:22
06/20/19
06/20
05:22
06/20/19
05:22
Upgrade
Scor rating change  »

Scor upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMS

Fresenius Medical

$39.49

1.175 (3.07%)

05:20
06/20/19
06/20
05:20
06/20/19
05:20
Upgrade
Fresenius Medical rating change  »

Fresenius Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$20.63

0.1 (0.49%)

05:16
06/20/19
06/20
05:16
06/20/19
05:16
Initiation
HP Inc. initiated  »

Deutsche Bank starts HP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 01

    Jul

  • 02

    Jul

  • 03

    Jul

  • 04

    Jul

DELL

Dell Technologies

$53.39

1.88 (3.65%)

05:15
06/20/19
06/20
05:15
06/20/19
05:15
Initiation
Dell Technologies initiated  »

Deutsche Bank starts Dell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

FNMA

Fannie Mae

05:12
06/20/19
06/20
05:12
06/20/19
05:12
Initiation
Fannie Mae initiated  »

Fannie Mae initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMCC

Freddie Mac

$0.00

(0.00%)

05:12
06/20/19
06/20
05:12
06/20/19
05:12
Initiation
Freddie Mac initiated  »

Freddie Mac initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$197.87

-0.65 (-0.33%)

05:12
06/20/19
06/20
05:12
06/20/19
05:12
Initiation
Apple initiated  »

Deutsche Bank, fearing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JBLU

JetBlue

$19.05

-0.21 (-1.09%)

05:07
06/20/19
06/20
05:07
06/20/19
05:07
Recommendations
JetBlue analyst commentary  »

JetBlue price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VYGR

Voyager Therapeutics

$27.87

0.05 (0.18%)

, SNY

Sanofi

$44.11

0.99 (2.30%)

05:05
06/20/19
06/20
05:05
06/20/19
05:05
Recommendations
Voyager Therapeutics, Sanofi, Neurocrine analyst commentary  »

Voyager Therapeutics…

VYGR

Voyager Therapeutics

$27.87

0.05 (0.18%)

SNY

Sanofi

$44.11

0.99 (2.30%)

NBIX

Neurocrine

$85.47

-0.28 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 16

    Sep

ORCL

Oracle

$52.69

-0.19 (-0.36%)

05:02
06/20/19
06/20
05:02
06/20/19
05:02
Recommendations
Oracle analyst commentary  »

Oracle price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BFAM

Bright Horizons

$141.18

1.73 (1.24%)

04:59
06/20/19
06/20
04:59
06/20/19
04:59
Upgrade
Bright Horizons rating change  »

Bright Horizons upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENBL

Enable Midstream

04:56
06/20/19
06/20
04:56
06/20/19
04:56
Initiation
Enable Midstream initiated  »

Enable Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.